| Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The companys products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts. |
